Breast Cancer Clinical Trials in Miami, FL

Breast Cancer Clinical Trials in Miami, FL

View the best 10 breast cancer medical studies in Miami, Florida. Access promising new therapies by applying to a Miami-based Breast Cancer clinical trial.

Trials in Miami, Florida

Here are the top 10 medical studies for breast cancer in Miami, Florida

Image of St. Joseph's Hospital and Medical Center in Phoenix, United States.

Fulvestrant +1 More

Estrogen Receptor Antagonist

Recruiting1 awardPhase 3
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Image of University of South Alabama - Mitchell Cancer Institute in Mobile, United States.

T-DM1 +1 More

Antibody Drug Conjugate

Recruiting1 awardPhase 3
This trial is being done to see if adding tucatinib to T-DM1 helps patients with HER2 positive breast carcinoma.
Image of Cancer Treatment Services Arizona in Casa Grande, United States.

Xoft® Axxent® eBx® IORT System®

Brachytherapy

Recruiting1 award
This trial is testing a device that gives a single dose of radiation during breast cancer surgery. It targets women with early-stage breast cancer to see if it works as well as the usual longer radiation treatments. The goal is to make treatment quicker and easier while still being effective.
Image of Site 537 Montefiore Medical Center in Bronx, United States.

BAL0891

Chemotherapy

Recruiting1 awardPhase 1
This trial tests a new drug, BAL0891, given to patients with severe cancer. It aims to find a safe and effective amount, both alone and with other cancer treatments. The goal is to determine the best amount that patients can handle.
Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Tamoxifen +1 More

Hormone Therapy

Recruiting4 awardsPhase 3
This trial is testing whether suppressing ovarian function and combining it with either tamoxifen or exemestane is more effective than tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer.
Image of Palo Verde Hematology Oncology in Glendale, United States.

Capecitabine +2 More

Antimetabolites

Recruiting2 awardsPhase 3
This trial will test if a new combination of drugs is more effective and safer than standard treatments for triple negative breast cancer.
Image of Memorial Sloan Kettering Basking Ridge (All Protocol Activities) in Basking Ridge, United States.

SDX-7320 +1 More

Recruiting0 awardsPhase 2
This trial is testing whether adding SDX-7320 to standard chemotherapy eribulin helps people with TNBC and metabolic dysfunction, and whether it is safe.
Image of University of Alabama at Birmingham in Birmingham, United States.

Risk-based Breast Cancer Screening Schedule

Behavioural Intervention

Recruiting1 award4 criteria
This trial is comparing annual breast cancer screening to a risk-based breast cancer screening schedule. The goal is to see if the risk-based schedule detects breast cancers earlier and causes fewer false positives.
Image of Ironwood Cancer & Research Centers in Chandler, United States.

Anastrozole +2 More

Aromatase Inhibitor

Recruiting3 awardsPhase 3
This trial will compare how well two treatments work in postmenopausal women with breast cancer. One treatment group will receive a nonsteroidal aromatase inhibitor plus abemaciclib. The other treatment group will receive a placebo plus abemaciclib.
Image of Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0028) in Marietta, United States.

Capecitabine +3 More

Antimetabolites

Recruiting2 awardsPhase 3
This trial will assess if pembrolizumab, when combined with chemotherapy, is more effective in treating hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer than chemotherapy alone. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) or overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1 and ≥10.

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.